The recent introduction of the selective BCL2 inhibitor venetoclax into the CLL treatment scheme has led to effective remissions for relapsed/refractory CLL patients, especially when combined with anti-CD20 antibodies [40, 41]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.